Patient preferences in advanced or recurrent ovarian cancer

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|23|3651-3659

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.23, 2014-12, pp. : 3651-3659

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer

By Dranitsaris G.  

PharmacoEconomics, Vol. 22, Iss. 6, 2004-01 ,pp. : 375-387

Adis International

Access to resources Recommend Favorite

Review of Dose-intense Platinum and/or Paclitaxel Containing Chemotherapy in Advanced and Recurrent Epithelial Ovarian Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3741-3753

Bentham Science Publishers

Access to resources Recommend Favorite

Gemcitabine enhances carboplatin for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

By Naumann R. Wendel  

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1397-1412

Adis International

Access to resources Recommend Favorite

Combination gemcitabine + cisplatin therapy for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite